Israel's first commercial medical cannabis export lands in Australia
While Israel first approved medical cannabis exports almost two years ago, issues with Ya'acov Litzman's 2017 reform have caused the process to stall
By IDAN ZONSHINEFrom right to left: Seach Medical Group CEO Yogev Sarid, Panaxia CEO Dadi Segal and Head of Israel's Medical Cannabis Unit Yuval Landschaf stand alongside the first commercial shipment of medical cannabis from Israel.(photo credit: Courtesy)
Panaxia, in cooperation with Seach Medical Group, two of Israel’s largest manufacturers of medical cannabis products, announced that the country’s first commercial export of medical cannabis flowers and products landed in Australia on Thursday, after the company received its export license on Sunday.Panaxia, which in June was approved for an EU-GMP standard license for the production and export of medical cannabis in European and international markets, and Seach Medical group, which grows cannabis flowers with a European standard license, were already prepared for the first shipment of medical cannabis flowers.The shipment was sent out from Panaxia’s factory in Lod through Ben-Gurion Airport on Sunday, immediately following the approval from Israel’s Health Ministry, which was given to the company on condition that it first ensure it has a steady enough supply of cannabis products to provide for Israeli patients, at an affordable price.Though the government first approved the export of medical cannabis for research purposes by BOL Pharma, in January 2019, it was only a year later that the first shipment of medical cannabis products was sent out overseas.Apart from that shipment however, the export market has been otherwise completely frozen since the announcement, after a botched reform in the medical cannabis market saw Israeli patients complain of a sharp rise in prices, a relative decrease in product quality and massive shortages.To combat the negative effects of the reform – which was led in 2017 by former health minister Ya’acov Litzman – Health Minister Yuli Edelstein, along with Deputy Health Minister Yoav Kisch, began a pilot program last month which mandated that Israel’s cannabis companies begin offering lower prices and steady supplies before they can receive approval to export their products overseas, to a market that has been estimated to net Israel between NIS 1 billion and NIS 4b.So far, the pilot program has seen mixed success, with some companies lowering prices for only certain strains, and most struggling to meet their supply standards, with Panaxia being the only company to be approved for export so far.Dadi Segal, founder and CEO of Panaxia, said of the announced shipment: “In recent years, we have worked day and night to reach the long-awaited moment in which we will realize our business vision and export medical cannabis outside the borders of Israel. I would like to congratulate Deputy Health Minister Yoav Kisch for leading the policy change and opening the export gates to the medical cannabis companies.“Israel is a world leader and a pioneer in the field of medical cannabis, and I have no doubt that Australia is just the first door to open,” he added.On Sunday, Panaxia also received the ministry’s approval to send medical cannabis products to Portugal, in a partnership with Canndoc, another veteran of the Israeli medical cannabis market.
Yogev Sarid, CEO of Seach Medical Group, said the company is “proud to be the first to export medical cannabis from Israel to the world commercially, and believes that this permit is the first sign of additional export permits to come. The export permit will allow Seach to further increase its market share and bring healing to thousands more patients.”He added that the company’s collaborations were the reason it was able to meet the pilot’s supply and pricing standards, saying: “Our significant and growing collaborations in Israel enable us to operate safely overseas while ensuring a steady supply of medical cannabis for all patients, in Israel and around the world.“We see great importance in continuing to lead the local market. We were the pioneers in the field in Israel, the first to market in pharmacies, and now the first to export commercially.” Sarid said. “We will continue to responsibly look for expansion opportunities, out of a desire to bring additional value to the company’s investors.”
